STOCK TITAN

Harrow Health Inc - HROW STOCK NEWS

Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.

Company Overview

Harrow Health Inc (HROW) is an innovative eyecare pharmaceutical company focused on addressing unmet medical needs through the discovery, development, production, and commercialization of specialized ophthalmic formulations and therapeutic products across the United States. Operating at the intersection of advanced research and clinical application, the company brings together deep industry expertise, rigorous R&D, and a commitment to improving patient care.

Business Model and Operations

At its core, Harrow Health provides a comprehensive portfolio that blends ophthalmology-based drug development with non-intravenous sedation and anesthesia therapeutics for a variety of medical procedures. Its operations are structured around:

  • Ophthalmic Therapeutics: Focusing on the management of ocular surface diseases, the company develops topical eye drop formulations that serve both preventative and therapeutic roles.
  • Compounded Medications: Offering both sterile and non-sterile formulations, it meets the needs of physicians seeking tailored solutions for diverse clinical scenarios.
  • Non-Intravenous Sedation: Developing products designed to facilitate conscious sedation during procedures such as cataract surgery, thereby enhancing patient comfort and procedural efficiency.

This multi-pronged approach not only diversifies its product portfolio but also creates a resilient business model that appeals to healthcare professionals and institutions across outpatient, in-office, and hospital settings.

Market Position and Competitive Landscape

Harrow Health Inc has carved a niche within the highly regulated US pharmaceutical market. Its strategic focus on ocular and sedation therapeutics differentiates it from broader scale pharmaceutical companies, while its commitment to advanced research and quality production standards reinforces its reputation among eyecare professionals. In a competitive landscape where precision and safety are paramount, Harrow Health’s integration of clinical insights with innovative drug formulations positions it as a noteworthy player devoted to addressing specific medical challenges effectively.

Product Portfolio and Therapeutic Solutions

The company has developed an extensive range of products that address conditions related to the ocular surface and procedural sedation. Its portfolio includes:

  • Topical Ophthalmic Formulations: Designed to manage diseases affecting the ocular surface and support rehabilitation of vision-related functions.
  • Compounded Medications: Both sterile and non-sterile, these are tailored to meet precise medical requirements across various treatment settings.
  • Sedation Therapeutics: Products intended for sublingual administration provide non-intravenous sedation, enabling safe and effective patient management during surgical procedures.

Research, Development, and Quality Assurance

The foundation of Harrow Health Inc’s operations lies in robust research and development. The company continually refines its product offerings through comprehensive clinical research and adherence to stringent quality assurance protocols. Its approach underscores a commitment to safety and efficacy while addressing the evolving needs of healthcare providers and patients. This rigorous scientific methodology exemplifies the company’s dedication to maintaining high standards of regulatory compliance and industry best practices.

Commitment to Scientific Integrity and Patient Care

Across its diverse operations, Harrow Health demonstrates a sustained commitment to improving patient outcomes. The company’s emphasis on continuous innovation, strategic R&D, and quality-focused manufacturing processes helps ensure that its pharmaceutical solutions not only meet but often exceed industry benchmarks. This dedication to scientific integrity and patient well-being has established Harrow Health as a trusted entity within the field of eyecare therapeutics.

Strategic Value Proposition

Harrow Health Inc’s value proposition is rooted in its specialized expertise in ophthalmic formulations and sedation therapies. By addressing critical gaps in current medical treatments, the company supports healthcare providers in delivering effective and accessible care. Its balanced focus on innovation, quality, and clinical relevance positions it as a vital contributor to the pharmaceutical landscape, particularly within the realms of eye care and procedural sedation.

Overall, Harrow Health Inc exemplifies a dedicated, research-driven approach to pharmaceutical development that leverages deep industry expertise to meet unmet medical needs. Through its integrated operations and commitment to quality, it remains a significant, unbiased source of therapeutic solutions for healthcare professionals nationwide.

Rhea-AI Summary
Melt Pharmaceuticals, Inc. (Melt) provided a corporate update, announcing the success of MELT-300 in its Phase 2 Pivotal Efficacy and Safety Study for procedural sedation in cataract surgery. The non-IV, non-opioid tablet, using Catalent Inc.'s fast-dissolving Zydis® delivery technology, is expected to begin Phase 3 program activities in the first quarter of 2024. Additionally, Melt settled its debt with its largest shareholder, Harrow, Inc. (Nasdaq: HROW), and secured funding for the Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
none
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED). The partnerships with PhilRx, Apollo Care, and PARx Solutions aim to simplify the prior authorization process, establish copay program deployment, and help prescribers overcome challenges. Harrow's commitment to patient access and innovative, affordable ophthalmic pharmaceutical products is reflected in its market access program for VEVYE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
partnership
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) has completed the transfer of the New Drug Application (NDA) for TRIESENCE, a synthetic corticosteroid used for various eye conditions, ahead of the previously agreed date. The company has also acquired the U.S. commercial rights to TRIESENCE and is making progress in manufacturing commercial batches. Harrow is implementing market access, marketing, inventory management, and brand-leveraging strategies to re-launch TRIESENCE in the U.S., showing a promising outlook for the company's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
Rhea-AI Summary
Harrow (Nasdaq: HROW) Announces Participation in Upcoming Conferences, BTIG 3rd Annual Ophthalmology Day and Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) - Harrow, a leading U.S. eyecare pharmaceutical company, reported record revenues of $34.3 million in the third quarter of 2023, marking a 50% increase over the prior-year revenues. The company also announced a GAAP net loss of $(4.4 million) and an adjusted EBITDA of $9.2 million, representing a 270% increase over the prior-year quarter. Additionally, Harrow completed the transfer of NDAs and launched several products in the U.S., including FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE®. CEO Mark L. Baum commented on the results, highlighting the exceptional performance of the IHEEZO® launch and the substantial increase in unit demand in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.01%
Tags
-
Rhea-AI Summary
Harrow, a leading U.S. eyecare pharmaceutical company, will release its financial results for Q3 2023 on November 13, 2023. The company will also provide a business update during a conference call and live webcast at 4:45 p.m. Eastern Time. Participants can access the webcast on harrow.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
Rhea-AI Summary
Harrow has completed the transfer of New Drug Applications for several eyecare pharmaceutical products and has launched them in the U.S. market. The company aims to increase brand awareness and sales through its marketing and sales teams. Product orders can be made through Cardinal's Cordlogistics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) changes its corporate name to Harrow, Inc. to align with its strategic focus on eyecare pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
Rhea-AI Summary
Melt Pharmaceuticals enters exclusive development and license agreement with Catalent for MELT-300, a sublingual formulation for procedural sedation during cataract surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
none
Rhea-AI Summary
Harrow announces record revenues of $33.5 million, a 44% increase YoY, and a net loss of ($4.2) million. Also reports record adjusted EBITDA of $11.0 million, a 144% increase YoY. Completed public offering of common stock for $69 million. Acquired commercial rights to several drugs. Expanded Oaktree Loan to $112.50 million. Positive financial performance and acquisitions may positively impact stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.45%
Tags

FAQ

What is the current stock price of Harrow Health (HROW)?

The current stock price of Harrow Health (HROW) is $23.52 as of April 4, 2025.

What is the market cap of Harrow Health (HROW)?

The market cap of Harrow Health (HROW) is approximately 821.3M.

What is Harrow Health Inc's primary focus?

Harrow Health Inc is primarily focused on developing and commercializing ophthalmic formulations and non-intravenous sedation therapeutics addressing unmet medical needs in the US.

What types of products does the company offer?

The company offers a range of products including topical eye drop formulations, sterile and non-sterile compounded medications, and sublingual therapeutics for procedural sedation.

How does Harrow Health Inc generate revenue?

Revenue is generated through the discovery, development, and commercialization of specialty pharmaceutical products, primarily within the ophthalmic and sedation therapy markets.

What differentiates Harrow Health from its competitors?

Its focus on specialized ophthalmic therapies combined with a comprehensive approach to non-intravenous sedation and robust R&D efforts distinguishes it within a competitive, regulated market.

In which market does Harrow Health primarily operate?

Harrow Health operates mainly in the United States, catering to healthcare providers and patients with unmet needs in eyecare and sedation therapies.

What role does research and development play in the company?

R&D is central to the company’s strategy, driving the design, refinement, and regulatory compliance of its pharmaceutical products to ensure safety, efficacy, and quality.

How does the company support clinical practices?

By providing a diversified portfolio of specialized medications, Harrow Health supports healthcare professionals in managing ocular conditions and delivering safe sedation during medical procedures.

Can you explain the company’s approach to quality assurance?

The company emphasizes strict adherence to quality assurance protocols and regulatory standards, ensuring that all products meet high benchmarks for safety and effectiveness.
Harrow Health Inc

Nasdaq:HROW

HROW Rankings

HROW Stock Data

821.29M
30.85M
13.49%
59.11%
7.72%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE